Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.88 |
| ▸ | DRD3 | P35462 | 20/20 | 0.88 |
| ▸ | DRD4 | P21917 | 3/20 | 0.88 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177150 | 1.00 | DRD2 (0.88) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4242439 | 1.00 | DRD2 (0.88) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL12661863 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL1842073 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL1840932 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL5188361 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4OPRM1 | |
| Water SCHEMBL1841645 | 0.93 | DRD2 (0.97) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4238881 | 0.88 | DRD2 (0.83) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4238880 | 0.88 | DRD2 (0.83) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4388560 | 0.88 | DRD2 (0.83) | DRD2DRD3DRD4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1758862-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | Pfizer Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005115985-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | PFIZER LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | DRD2, DRD1, DRD3 | DRD2 1/4885DRD3 3/4885DRD4 5/4885 |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | DRD2, DRD1, DRD3 | DRD2 1/4885DRD3 3/4885DRD4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.